VERTEX PHARMACEUTICALS INC / MA (VRTX) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 253.46M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 253.46M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 253.46M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 253.46M | (m) | (m) |
| 2026-03-31 | 253.81M | (m) | (m) |
| 2025-12-31 | 254.03M | (m) | (m) |
| 2025-09-30 | 253.72M | (m) | (m) |
| 2025-06-30 | 256.39M | (m) | (m) |
| 2025-03-31 | 256.80M | (m) | (m) |
| 2024-12-31 | 256.79M | (m) | (m) |
| 2024-09-30 | 257.53M | (m) | (m) |
| 2024-06-30 | 258.10M | (m) | (m) |
| 2024-03-31 | 258.05M | (m) | (m) |
| 2023-12-31 | 258.31M | (m) | (m) |
| 2023-09-30 | 257.68M | (m) | (m) |
| 2023-06-30 | 258.09M | (m) | (m) |
| 2023-03-31 | 257.55M | (m) | (m) |
| 2022-12-31 | 257.09M | (m) | (m) |
| 2022-06-30 | 256.46M | (m) | (m) |
| 2022-03-31 | 255.76M | (m) | (m) |
| 2021-12-31 | 254.58M | (m) | (m) |
| 2021-09-30 | 254.25M | (m) | (m) |
| 2021-03-31 | 258.87M | (m) | (m) |
| 2020-12-31 | 259.96M | (m) | (m) |
| 2020-06-30 | 260.47M | (m) | (m) |
| 2020-03-31 | 259.28M | (m) | (m) |
| 2019-12-31 | 259.27M | (m) | (m) |
| 2019-09-30 | 257.15M | (m) | (m) |
| 2019-06-30 | 257.04M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |